Acadia Pharmaceuticals
San Diego, California, United States · Biopharma, Biotechnology, Health Care
Acadia is advancing breakthroughs in neuroscience to elevate life. For 30 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis and the first and only FDA-approved drug for the treatment o
You have opened 5 full company profiles today. Create an account to keep reading them. Create an account
Key facts
- Headquarters
- San Diego, California, United States
- Employees
- 501
- Industries
- Biopharma, Biotechnology, Health Care
- Status
- Public (ACAD)
- Website
- acadia.com
- Company page
Recent activity at Acadia Pharmaceuticals
- : Acadia Pharmaceuticals Announces Departure of Elizabeth H.Z. Thompson, Ph.D.
- : SEC 8-K (5.02): On October 23, 2026, Elizabeth H.Z. Thompson, Ph.D., the Executive Vice President and Head of Research and Development at Acadia Pharmaceuticals Inc., officially departed from her position after announcing her retirement on April 27, 2026. While Dr. Thompson will no longer serve as an employee, she will continue to contribute to the Company in a consulting capacity until December 31, 2026. The Company is actively working to find her replacement. This transition marks a significant change in leadership for the Research and Development division, which may influence ongoing and future projects.
- : SEC 8-K (7.01): On September 24, 2026, Acadia Pharmaceuticals Inc. announced the topline results from the Phase 2 portion of its ongoing RADIANT clinical trial program. This trial evaluates the effectiveness of remlifanserin, targeting hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP). The results are significant as they pave the way for Phase 3 trials, potentially impacting treatment options for ADP. The press release detailing these results is included as an exhibit in the 8-K filing, emphasizing the company's commitment to advancing therapeutic solutions in this area.
Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.
Employee benefit plans
Acadia Pharmaceuticals files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
About Acadia Pharmaceuticals: questions and answers
What does Acadia Pharmaceuticals do?
Acadia is advancing breakthroughs in neuroscience to elevate life. For 30 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis and the first and only FDA-approved drug for the treatment o
Where is Acadia Pharmaceuticals headquartered?
Acadia Pharmaceuticals is headquartered in San Diego, California, United States.
How many employees does Acadia Pharmaceuticals have?
Acadia Pharmaceuticals has about 501 employees.
What is the latest news on Acadia Pharmaceuticals?
On Oct 23, 2026, Acadia Pharmaceuticals Announces Departure of Elizabeth H.Z. Thompson, Ph.D.
Is Acadia Pharmaceuticals a public company?
Yes. Acadia Pharmaceuticals is publicly traded under the ticker ACAD.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy